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Abstract
Objective: Develop a simple method for optimal estimation of HIV incidence using the BED capture enzyme immunoassay.
Design: Use existing BED data to estimate mean recency duration, false recency rates and HIV incidence with reference to a
fixed time period, T.
Methods: Compare BED and cohort estimates of incidence referring to identical time frames. Generalize this approach to
suggest a method for estimating HIV incidence from any cross-sectional survey.
Results: Follow-up and BED analyses of the same, initially HIV negative, cases followed over the same set time period T,
produce estimates of the same HIV incidence, permitting the estimation of the BED mean recency period for cases who
have been HIV positive for less than T. Follow-up of HIV positive cases over T, similarly, provides estimates of the false-recent
rate appropriate for T. Knowledge of these two parameters for a given population allows the estimation of HIV incidence
during T by applying the BED method to samples from cross-sectional surveys. An algorithm is derived for providing these
estimates, adjusted for the false-recent rate. The resulting estimator is identical to one derived independently using a more
formal mathematical analysis. Adjustments improve the accuracy of HIV incidence estimates. Negative incidence estimates
result from the use of inappropriate estimates of the false-recent rate and/or from sampling error, not from any error in the
adjustment procedure.
Conclusions: Referring all estimates of mean recency periods, false-recent rates and incidence estimates to a fixed period T
simplifies estimation procedures and allows the development of a consistent method for producing adjusted estimates of
HIV incidence of improved accuracy. Unadjusted BED estimates of incidence, based on life-time recency periods, would be
both extremely difficult to produce and of doubtful value.
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Introduction
For infections of long duration, prevalence estimates are less
informative than incidence as measures of the state and trajectory
of an epidemic. For HIV, where infection durations can exceed a
decade even for patients not on antiretroviral therapy (ART) – and
can be even longer for patients who are – incidence estimates are
particularly important. However, whereas HIV prevalence is
relatively easy to measure, HIV incidence is much more difficult.
Even the so-called ‘‘gold standard’’ approach, involving follow-up
of cohorts of initially HIV negative cases, is not without bias and is
costly, time consuming and logistically challenging.
Ideally one could calculate incidence from the samples collected
in cross-sectional surveys used to estimate HIV prevalence – if it
were possible to identify, from among the HIV positive cases, those
that had become infected within some specified period prior to the
time of the survey. Various methods have been suggested for
identifying so-called ‘‘recent infections’’; none is so far entirely
satisfactory and research into improved methods is on-going. A
widely used approach is the BED Capture Enzyme Immuno-Assay
(BED-CEIA or simply BED) assay which has been used alone, or in
combination with an avidity assay, to estimate HIV incidence [1].
A common problem with the assay is that, when applied to
arbitrary cross-sectional survey data, the resulting HIV incidence
often over-estimates the true values [2]. This problem has led to
considerable discussion [3,4,5,6,7,8,9], but to no general agree-
ment on how best to proceed. In this paper we suggest a fresh
approach, which resolves difficulties with the BED method and,
more generally, provides a simple improved approach to HIV
incidence estimation using biomarkers.
Methods
The BED method is based on the increasing proportion of anti-
HIV-1 immuno gamma globulin (IgG) in total IgG following
seroconversion [1]. People are classified as ‘recent’ seroconverters
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linked immunosorbent assay and have a normalized optical
density (OD) below a pre-set cut-off (C) on the BED assay.
The method was first characterized for use on clade-C HIV
virus using samples collected during the ZVITAMBO Trial,
carried out in Harare, Zimbabwe between October 1997 and
January 2000 [3]. Of 14,110 women and their babies, recruited
within 96 hours postpartum, 9562, 4495 and 53 mothers tested
HIV negative, positive and indeterminate, respectively (Figure 1).
All were followed up at 6-weeks, and at 3, 6, 9 and 12-months
postpartum; surviving mothers were retested for HIV at each
follow-up visit. Of the original HIV negative mothers N=6595 still
tested negative at 12-months postpartum, at which time all HIV
positive mothers were also tested using BED. Of the PN=234
seroconverters, and the PP=3010 who had previously tested
positive at baseline, RN=123 and RP=156, respectively, had a
BED OD,0.8 when they were tested at 12-months postpartum.
These R=RN +RP cases were classified as recent seroconversions –
where ‘‘recent’’ means that seroconversion is supposed to have
occurred within the previous $|365 days – this period is termed
the mean recency duration (previously ‘‘window’’ [3]), appropriate for
the chosen BED cut-off 20.8 in the case of the ZVITAMBO
study.
Results
Defining the problem
The detailed follow-up data allowed the estimation of HIV
incidence over 12 months directly from the frequency of
seroconversions observed at each of the first five post-natal visits,
and also allowed the estimation of v and, thereby, the BED
incidence. If seroconversions are uniformly distributed during the
first 12-months postpartum their number is estimated by R/v and
the cumulative incidence,o rrisk ( 0) that an HIV-1-negative woman
seroconverted in the 12-months postpartum, can be estimated by:
J
^
0~
R=$
R=$zN
~
r0
r0zN
: ð1Þ
where r0=R/v, N is the number testing HIV negative at follow
up, and where we use the symbol to indicate annualized risk of
infection, reserving the symbol I for the incidence rate, see below.
With N=6595, P=PN + PP=3244, R=279 and v=0.512
years (187 days), the unadjusted BED incidence estimate is
J
^
0~7:6%(95% CI; 6.7%–8.5%). By comparison the follow-up
estimate was J
^
FU~3:4%(95% CI, 3.0–3.8) [3], 55% lower than
the BED estimate: this discrepancy needs to be explained.
One suggestion is that the difference is primarily due to the
existence of a proportion (e) of the population that tests as recently
infected despite having been HIV positive for very much longer
than v – typically more than twice as long. For example, in the
ZVITAMBO study, 156/3010=5.2% HIV positive cases tested
recent by BED at 12-months postpartum, despite having been
infected for more than a year. Various mathematical adjustments
have been suggested to counter this problem [3,4,10].
An alternative interpretation is that the problem arises because
v, as estimated for instance in [3], under-estimates the population
mean recency period. This period, henceforth vP, is defined as the
total time that an HIV case tests as a recent infection during his/
her entire life after infection – including times when the case re-
enters the recent state. It has been argued that, if vP were
appropriately estimated, adjustment would largely be unnecessary
[5]. Moreover, it was claimed [5] that two suggested adjustment
procedures either had no effect on the incidence estimates [4], or
contained a mathematical error, which led to substantial under-
estimates of HIV incidence [3].
This view has been countered with the demonstration that, for
there to be a match between follow-up and BED unadjusted
estimates of incidence, an unfeasibly long value of v=1.202 years
(439 days) would be required [6]. This argument was, in turn,
rejected on the grounds that there is no reason to suppose that the
two incidence estimates should be the same [7]. The reason for this
is that the follow-up estimate refers only to the 12-months
postpartum period, whereas any biomarker estimate applied at 12-
months postpartum will be estimating the incidence averaged over
a longer period – including, in the ZVITAMBO example, the pre-
partum (pregnancy) period when incidence will likely be higher.
BED and follow-up incidence estimates over the same
time period
This last argument, which may be regarded as the point of
departure for the present paper, refers to the situation where the
BED analysis is applied to all of the ZVITAMBO 12-month data.
Consider, however, the case where the BED analysis is applied to
the 12-month data that arose only from the 9562 women who
tested negative at baseline – i.e., the 6595 who were seen at the 12-
month follow-up visit and who still tested HIV negative at that
time, and the 123 cases among the seroconverters who tested
recent by BED (Figure 1). Now both the BED and follow-up
incidence estimates refer, unequivocally, only to the 12-months
postpartum period – because, given our data selection, no case has
been HIV positive for longer than 12 months. The BED analysis
applied to these data should provide approximately the same
incidence as the follow-up procedure, and the appropriate value
for the mean recency period in Equation (1) is thus the value that
ensures this equality. Setting N=6595, R=123 and J
^
0~0:034 in
Equation (1):
$T
^
&
R(1{J
^
FU)
J
^
FUN
~
123(1{0:034)
0:034X6595
~0:530 years ~ 194 days
where vT, is now defined as the mean time spent in the test-recent state
while infected for less than T [11], where T=365 days for the
ZVITAMBO analysis. We return later to the problem of how best
to estimate$T; but notice that the value of 194 days is only 3.7%
higher than the 187 days estimated from the pattern of increase of
BED OD among seroconverters in the ZVITAMBO study [3].
Figure 1. Summary of baseline and 12-month postpartum HIV
results and, for the latter, of the BED results for HIV positive
cases.
doi:10.1371/journal.pone.0029736.g001
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J
JNotice also that vT will indeed under-estimate vP, as correctly
pointed out in [5]; and whereas vT is clearly the appropriate mean
recency period for the problem analyzed in the previous
paragraph the question arises whether we should be using vT or
vP when analyzing normal cross-sectional survey data.
Reducing the problem
This question can be addressed by the following thought
experiment. Suppose we were presented with the full 12-month
ZVITAMBO data as shown in Figure 1 but where everybody was
being seen for the first time – i.e. we simply saw 6595 HIV negative
and 3244 positive cases. Suppose now that we had a test that was
similar to the currently available BED test, except that it always
correctly identified positive infections as long-term – as long as
they had been HIV positive for more than one year. Under such
circumstances we would only see 123 BED-recent cases, we would
ignore all other HIV positive cases and the analysis would be
reduced to the above situation involving these 123 recent cases and
the 6595 negatives. We would then, again, be estimating an
incidence that referred only to the previous 12-month period and
it would again be appropriate to use vT as the mean recency
period. One could equally reduce the analysis to this simpler
situation if clinical information allowed the identification of
individuals HIV infected for more than a year – regardless of
their BED test result.
Extension to all BED incidence estimates
The simple situations described in the previous section do not
generally exist in African settings where people in cross-sectional
surveys are subject to anonymous testing, and where there is no
information about previous HIV testing history. The question then
arises: ‘‘Is there, nonetheless, any way in which we can reduce the
BED analysis to the simpler situation involving only HIV negative
cases and the number of cases that have been HIV positive for less
than some defined convenient short period of time, T?’’
The answer to this question is ‘‘yes’’ – as long as we have a good
estimate of e, the proportion of people in the population under study
that will test recent by BED if they have been HIV positive for
time . T. Applying e to the BED results of a cross-sectional survey
we can estimate the number of these long-term false-recent cases
without needing to know which those cases are. We then simply subtract
this number from R (the total number testing recent – correctly or
falsely) and the analysis reverts to that involving only the HIV
negative cases – and the remainder of the recent cases. The
incidence over the time period T prior to the survey is then
estimated as before from Equation (1), using the mean recency vT,
where vT is expressed as a proportion of T. The following
provides an outline (see Supporting Information S1 for derivation)
of the algorithm required to achieve this.
If R provides a first estimate of the number of recent
seroconversions then, assuming a uniform distribution of sero-
converters over the previous time T, a first approximation of the
estimated number (r0) of cases that have seroconverted in the
previous time T is given by r0=R/vT , and a first estimate of the
incidence is, using Equation (1), J
^
0~r0=(r0zN). The first
estimates (p1) of the number who have been HIV positive for
longer than T is p1~P{r0. But, by assumption, a proportion e of
the p1 cases, that have been HIV positive for longer than T, still
test recent by BED. A better estimate of the number of cases who
seroconverted in time T prior to the survey is thus given by
r1~(R{ep1)=$T, which provides an improved estimate, J1,o f
the incidence and the basis for an iterative procedure, which
converges rapidly. With the ZVITAMBO input data, and
assumed values of vT=0.513 (187 days) and e=0.0517, as
iR‘, riR123, epiR156, the number known to be long-term false-
recent cases (Figure 1), and J
^
i~ri=(rizN)?3:4%, the value
observed from the follow-up study.
The exact match to the follow-up incidence in the ZVITAMBO
Trial is artificial, because we have used the value of e derived from
the observed number of long-term false-recent cases in the same
data set. As pointed out previously, any adjustment procedure will
only be useful if estimates of e are applicable to the analysis of
BED data from other similar populations. The present example is
merely provided to establish the principle of how the adjustment
procedure functions. The idea is simply to reduce the problem to
the equivalent situation where we estimate incidence from the
number of recent seroconverters among cases that were HIV
negative at time T prior to the survey. It is then appropriate to use
vT as the estimate of the mean recency period and the incidence
refers to the period, T, over which both vT and e are defined. Nor
does the period over which the incidence is estimated need to be
12 months: this period was used in the analysis of the
ZVITAMBO data only because clients were followed most
intensively at the 12-month visit and thus provided the most
complete data for BED analysis.
Closed form solution
Formally, the above iterative procedure converges to the
following closed form solution for the adjusted risk of infection:
JT
^
~
R{eP
Rz$TN{e(NzP)
ð2Þ
where vT is a (dimensionless) proportion of T. For comparison
with more recent results [10], note that the same derivation
procedure (see Supporting Information S1) also produces an
estimator for the instantaneous incidence rate:
I
^
T~
R{eP
(VT{eT)N
ð3Þ
where VT~$TT. A more formal mathematical development
produces the same result [11].
Whereas Equation (2) was originally presented as a simplifica-
tion of the adjustment in [4], it was actually derived as shown in
the Supporting Information S1. This shortcut, and the failure to
note the importance of strictly relating the mean recency period to
those cases that had been HIV positive for less than a year, has led
to considerable misunderstanding, which is resolved in the
following sections. Note that whereas, in making the simplification
(see equation (3) in [3]) we set v=0.5, the derivation here (see
Supporting Information S1) shows that this assumption is not
necessary; nor is it necessary to stipulate that the incidence is to be
estimated over a year (see above) and finally, it is not necessary to
assume equality between the sensitivity (s: the probability that a
case HIV positive for time t,vT has BED OD,C) and short-term
specificity (r1: the probability that a case HIV positive for time
vT,t,T has BED OD$C [3].
Definitions of the long-term false-recency rate
Equation (2) has been criticized on the grounds that, under the
assumptions of its derivation, e must necessarily take the value zero
[5]. The problem lies in the use of different definitions of the mean
recency period and the long-term false recency rate. The symbol e
was first defined in this context from the ZVITAMBO data as the
proportion of cases that were ‘‘misclassified as recent seroconver-
ters at least a year after they first tested HIV-1 positive’’ [3]. In
Estimating HIV Incidence with BED
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as used in [4] and the problem is that these workers effectively use
two estimates ofr2 which differ in a crucial way. The value actually
used in their adjustment was ‘‘the overall rate of false positives (1-
specificity)’’ and was ‘‘based on analysis of specimens from longer-
term-infected individuals not known to have clinical AIDS,
opportunistic infections, or to be on treatment’’. This practical
definition is the same as the one used for e in [3] and makes no
assumption regarding the source of the false positives.
However, in the analysis of the probability of remaining in the
recency period,r2 was also defined as the specificity over the
period greater than twice the recency period after seroconversion,
‘‘where the curve is flat’’ [4]. This is the sense in which
Brookmeyer [5,9], and also McWalter and Welte [10,12], use
the term and is the probability, PNP [10], that a case never leaves
the recent state.
A necessary condition for these two definitions to be congruent,
with PNP=e, is that no cases exist where persons re-enter the
recency state after having exited. This is explicitly assumed in [5]
but evidence to the contrary had already been published [3]. The
point will now be explored more fully since it lies at the heart of
the confusion and its clarification should lead to a reconciliation of
the divergent views on the best way to estimate HIV incidence
from BED data.
Reversions to the recent state: time courses of changes in
BED optical density
In Figure 2A we sketch the combinations of OD values observed
at baseline (t=0) and 12-months later (t=1) in ZVITAMBO – and
then consider possible values of the OD for times t,0 and t.1 that
are consistent with these observations. Of those who were HIV
positive at t=0, and tested positive again at t=1, 95% (2607/
2749) had a BED OD.C=0.8 at t=1; these ‘‘normal’’ scenarios
are not illustrated in Figure 2. The concerns surround the
histories, observed and implied, of the 142 cases illustrated by
Cases 1–3, which were HIV positive at t=0 but then had a BED
OD,C at t=1. Case 1 typifies the situation, observed in 103/142
(73%) cases in ZVITAMBO, with BED OD,C both at t=0 and
t=1. Such cases, if they had an OD,C for all t.0, constitute the
group sometimes used to define e [5,9] and, equivalently, PNP [10].
But this is not the way that e was defined in [3], because the
above definitions exclude the situations typified by Case 2, and
explicitly reported for 39 cases in ZVITAMBO, ([3]; page 515,
first paragraph), where OD.C at t=0 and OD,C at t=1. That is
to say, 39/142=27% of the cases constituting the original
definition of e were BED long-term at baseline but had reverted
to the recent state a year later. Moreover, 27% is only a lower
bound for the probability of reverting. Thus, since cases can revert,
we must allow the possibility that any particular case with OD,C
at t=0 and t=1 had actually both left the recent state, and then
reverted, at some time prior to t=0, as illustrated in Case 3. In
principle, therefore, we can only say from the ZVITAMBO data
that the probability of reverting lies between 27% and 100%.
Possible time courses of changes in BED OD over the life of an
HIV positive case are summarized in Figure 2B.
Indications that reverting cases form an important proportion of
e were obtained from the ZVITAMBO seroconverting panels for
cases followed up for sufficiently long that they were known to have
been HIV positive for 365 days – i.e. the time between the first
HIV positive test and some later test exceeded 365 days. There were
51 such seroconverting cases, only one of which (2%) never left the
recent state. This provides a first estimate of PNP, which is less than
half of the estimate of e. We caution, however, that even though
the one case that failed to leave the recency period was followed
for .700 days after seroconversion, there is no guarantee that the
OD failed thereafter to exceed 0.8. In this sense 2% is an upper
bound for PNP. On the other hand, this is a very crude estimate
given the small sample size; the 95% confidence interval for the
Figure 2. A. Patterns of changes in BED optical density showing the range of scenarios actually observed in the ZVITAMBO Trial
and possible changes before and after the observational period. Clients were first seen at time 0 and then again a year later. For purposes of
illustration it is assumed that all cases had seroconverted two years previously at which time they had a BED OD close to zero. See the text for
discussion of possible changes in BED OD before the clients were tested at t=0 and again after they were tested at t=1. B. Possible long-term
changes in BED OD following HIV infection.
doi:10.1371/journal.pone.0029736.g002
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area is now of extreme importance.
Implications of reversion to the recent state for models of
BED
Models for the BED method have assumed a situation, pictured
in Figure 3, where the probability of a case remaining in the recent
state declines monotonically, either to some low constant level .0,
termed PNP in [10], or ultimately to zero if, as argued in [5], no
case stays in the recent state for more than about three years. In
either event the function is used to derive an identity relating the
BED sensitivity (s) and the short and long term
specificities(r1 and r2):
s{r1zr2~1 ð4Þ
If this identity is correct and if, as assumed in [3], s~r1, then it
follows that 1{r2~e~0, contrary to the assumption in [3] and
pointing therefore to a mathematical error in Equation (2) [5].
There are two problems with the argument: 1) It is based on a
population estimate of the mean recency (vP), as opposed to the
estimate actually used to estimate e, which was approximately the
same as vT and thus ,, vP. 2) It failed to take into account
published evidence that cases can revert to the recent state at
time(s) t.T , so thatewPNP§0. The argument in [5] thus
provides no evidence of a mathematical error in Equation (2).
Indications, from a numerical example [5], that Equation (2)
massively under-estimates HIV incidence, leading inevitably to
negative estimates of HIV incidence where there are large
numbers of prevalent long-standing infections, arise from
confusion over the definitions of vT vs vP and e vs PNP.
This point is illustrated by a numerical example using the
ZVITAMBO data. Suppose the data were as shown in Figure 1,
except that 100,000 women tested HIV positive at baseline and
again 12 months later. Then at 12-months postpartum the data
would have consisted of N=6595, P=234+100,000 and R=123 +
e6100,000<5289 – assuming 5.166% of all women HIV positive
for more than 12 months test recent by BED. Inserting these data
into Equation (2) produces a value of JT=3.5% as with the
original ZVITAMBO data. Negative estimates of incidence do not
thus arise from Equation (2) simply through large numbers of
prevalent long-standing infections. They can, however, arise from
the use of inappropriate values of e [3], and/or the mean recency
period and/or from counting errors.
Given the reality of cases reverting to the recent state, what is
evident from Figure 3 is that functions presented as relating the
time since infection to the probability of being in the recent state
[5,10], do not decline monotonically and are thus not survival
function in the normally understood sense. During the period [0,
T] the BED OD generally increases rapidly and the vast majority
of cases will therefore leave the recent state at some time t,T.
Thereafter, however, if cases start reverting to the recent state, the
‘‘survival’’ function increases – in some way that we have not yet
measured or understood – from PNP towards some higher level
such that if we take a cross-sectional survey we see a proportion
e.PNP of cases which test recent by BED when they are known to
have been HIV positive for t.T. Models for BED [5,10], need to
be modified to take account of cases that, permanently or
temporarily, re-enter the recent state. An improved model of this
type has now been developed [11].
Estimating vP and vT
We now return to the problem of estimating mean recency
periods from follow-up data. With reference to the scenarios
encapsulated in Figure 2A and B, the ideal case would be one
where, invariably, the OD increases with time, eventually leaving
Figure 3. Changes in the probability of testing recent by BED with time since HIV infection. For PNP=0 there are no ‘‘non-progressors’’ –
i.e. it is assumed that every person, at some point, has a BED OD.C, the pre-set OD cut-off. For PNP.0 some people never have an OD.C. In both
cases, however, it is allowed that some cases may revert, temporarily or permanently – i.e. that the OD declines from .0.8 to ,0.8. Note that this
implies that the level of e may vary with the time since seroconversion and, in particular, may not even (as illustrated for simplicity) increase
monotonically with time.
doi:10.1371/journal.pone.0029736.g003
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develops late stage AIDS or initiates ART. It is assumed that such
patients could be identified and excluded from the recency
estimation procedure. The mean recency is then relatively easily
estimated since one is only looking for the first passage time to C.
The ZVITAMBO Trial produced, however, at least one case
where follow-up for at least 714 days post-seroconversion never
produced a BED OD.0.1. One must allow the possibility that this
case would stay in the recent state indefinitely. Similarly, some
cases do revert to a recent state and we cannot know whether those
that revert stay in the recent state indefinitely or whether they
‘‘flip-flop’’ one or more times between the states.
These complications suggest that vP, as defined in [5], could
never practically be estimated. Thus, it is stated that the mean
recency period should include the total time for which OD,C –
i.e., the initial time plus any subsequent times when the OD dips
below C. But if the OD might drop below C at any time, or shows
no signs of ever being greater than C, or flip-flops between the
states, then this means that in order to estimate vP it would be
necessary to follow individual seroconverters for their entire lives.
This was never feasible, and will now be quite impossible given the
ethical objections to following HIV positive persons for the
requisite time without giving them access to ART. Given these
problems and that the full distribution of recency periods has a
very long tail it is also obvious that estimates of vP, even if they
could be obtained, would come with unacceptably large errors.
The motivation for estimating the population mean recency
period vP is to obviate the adjustment procedure [5]. Even if this
were possible, which seems unlikely given the foregoing, it may not
even be desirable. Thus, as pointed out in [5], the cross-sectional
biomarker approach, applied using vP, estimates a time-weighted
average of incidence prior to the time of the survey, where the
weighting function is the backward recurrence time density which
depends on the entire mean recency period distribution including
its tail. In the ZVITAMBO context, the BED method would then
estimate incidence over a period that could extend, for some
unknown time, into the pre-partum (pregnancy and even pre-
pregnancy) period. Having an incidence estimate which spans
some ill-defined time period, and is dependent on some complex
and currently undefined weighting function does not seem
particularly helpful.
By contrast, as evidenced by the ZVITAMBO study, the
estimation of a censored mean recency period, vT, and the
associated adjustment factor e, is a relatively straightforward
matter and the estimates come with acceptable levels of error.
Moreover, the procedure gives rise to incidence estimates that
refer to a well defined period, T, of order one year. Further major
advantages are: i) One can largely ignore the effects of mortality,
which should be minimal during periods of order one year post-
seroconversion. ii) There is no need to address the difficult matter
of weighting in situations where we can assume incidence has
changed little over time T.
In estimating the mean recency period from the ZVITAMBO
BED data, seroconverter panels were excluded if the range of ODs
did not span the pre-set OD cut-off (C) [3,13]. Panels were thus
excluded if the OD at the time of the first HIV positive test was
greater than C, or if the maximum OD among all BED tests was
less than C. The net effect of this was to produce an approximation
to a censored mean recency period, vT, as defined above. An
unbiased estimate of vT is provided by R/S [11] where S is the
number of HIV positive cases observed at time T, among those
HIV negative at time 0, and R is the number of these
seroconverters that test recent by BED. For ZVITAMBO, with
T=365 days, $
^
T =R/S=123/234=0.526 years=192 days
(Figure 1). The estimating procedure for vT in [3] thus produced
a biased result – but the difference (187 days vs 192 days) is small,
as are the differences between these two estimates and the 194
days required to produce an exact match between the
ZVITAMBO BED and follow-up estimates of HIV incidence
(see above). Given the similarity in the results derived from these
various approaches to estimating vT it seems likely that further
improvements in its estimation will lead only to minor improve-
ments in the accuracy of the BED method of estimating HIV
incidence.
Biases in BED adjustment procedures
A more complete, and complex, development of the theory
underlying the use of biomarker estimates of HIV incidence
provided, inter alia, a maximum likelihood estimate of the adjusted
BED incidence rate:
I
^
mw~
R{PNPP
$(1{PNP)N
ð4Þ
wherePNP, as defined above, is the probability that the OD never
exceeds the pre-set OD cut-off C. This formulation was used to
estimate the biases in the adjustment given by Equation (2) [12]. In
practice the differences between the various adjustments are small
compared with the counting errors. Thus, using the 12-month
ZVITAMBO data, Equation (4) gives an annual incidence rate of
3.46%, compared to 3.65% from Equation (3). Moreover,
Equation (4) has now been superseded and the new incidence
estimator is identical to Equation (3), if both use the same mean
recency period [11].
Discussion
A recent review of measuring the HIV/AIDS epidemic repeats
the idea that long-term-false-recent cases may be ascribed
variously to assay non-progressors, elite controllers, persons in
late-stage HIV and/or cases on ART [14]. The higher level of
total IgG in African than in Western countries, due to higher
exposure to other pathogens, also increases the risk of misclassi-
fication. While these cases must of course be dealt with
individually, our analysis shows that even when they have all
been removed, HIV incidence will still be over-estimated where
there are cases that revert to the recent state. And that problem
can, currently, only be dealt with using mathematical adjustments
[3,4,12].
The importance of mathematical adjustments of BED estimates
of HIV incidence arises from the fact that we cannot, even in
principle, estimate the population mean recency period (vP).
Because we are unable to follow up cases for long enough, all
estimates from follow-up data under-estimate vP, and thus over-
estimate HIV incidence. Restricting our view to a time period T
means that we neither need, nor want, to estimate vP. Instead we
use vT – which is easier to estimate – and then adjust for the
number of cases that have been HIV positive for longer than T,
and still test recent by BED.
The adjustments provided in Equations (2) and (3) will all only
be as good as the value of e – and therein lies a problem. If an
important component of e is due to reversion to the recent state,
and if this reversion can occur at any time and is not solely or even
mainly associated with late-stage disease, then we expect that e
might vary quite rapidly with time, even in a single population.
As pointed out in the original analysis of the ZVITAMBO data,
high variability in e would be sufficient to render the BED method
of little general use [3]. The scientific community has been slow in
Estimating HIV Incidence with BED
PLoS ONE | www.plosone.org 6 January 2012 | Volume 7 | Issue 1 | e29736investigating such variability and it is fruitless to speculate further
about such variability and its origins. What is nonetheless clear is
that there is an urgent need for tests that are able to identify long-
term infections with much greater certainty than the BED method.
Use of such a test, either by itself or in conjunction with the BED
method, would constitute a major advance in estimation and
would, inter alia, remove the necessity for mathematical adjust-
ments in the estimating procedure.
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